India has so far administered 543,846,290 vaccine doses. That is 1689.35 per cent of its total caseload, and 38.99 per cent of its population
Sunday is the deadline for consumers to take advantage of a special sign-up period for private coverage made more affordable by his relief law.
Drug firm JB Chemicals & Pharmaceuticals on Thursday reported a consolidated net profit of Rs 119.05 crore for the quarter ended on June 30, 2021. The company had posted a net profit of Rs 119.50 crore for the corresponding period of the previous fiscal, JB Chemicals & Pharmaceuticals said in a filing to BSE. Consolidated revenue from operations of the company stood at Rs 606 crore for the quarter under consideration. It was Rs 522.3 crore for the same period a year ago, it added. "The organisation continues its strong performance well in the first quarter of the financial year. On the domestic front, we are one of the fastest growing companies in the industry," JBCPL CEO and Wholetime Director Nikhil Chopra said. While demand trends in international business continue to be volatile (given the COVID situation); the company's key markets like the US, South Africa have outperformed and even Russia/ CIS are seeing gradual signs of revival, he added. Shares of JB Chemicals & ..
India has so far administered 523,671,019 vaccine doses. That is 1632.5 per cent of its total caseload, and 37.54 per cent of its population
The transaction is based on an enterprise value of $1.2 billion, subject to closing adjustments, and is expected to conclude within 90 days
India has so far administered 508,664,759 vaccine doses. That is 1591.07 per cent of its total caseload, and 36.47 per cent of its population
India has so far administered 506,810,492 vaccine doses. That is 1587.03 per cent of its total caseload, and 36.333 per cent of its population
India has so far administered 489,342,295 vaccine doses. That is 1538.22 per cent of its total caseload, and 35.05 per cent of its population
India has so far administered 478,544,114 vaccine doses. That is 1508.34 per cent of its total caseload, and 34.31 per cent of its population
Riding on huge investor interest in the healthcare sector, five pharma companies are tapping the initial public offering (IPO) market over the next couple of weeks to raise over Rs 8,000 crore. The list include the Rs 4,000-crore IPO by the Bain Capital-backed Emcure Pharma, the Rs 1,500-crore issue by Vijaya Diagnostic Centre, diagnostic firms Krsnaa Diagnostics (Rs 1,200 crore) and Mumbai-based bulk drugs maker Supriya Lifesciences (Rs 1,200 crore), and pharma formulations contract development and manufacturer (CDMO) Windlass Biotech's Rs 400 crore issue. Investment bankers estimate these five companies to together raise over Rs 8,300 crore through the public offerings this month. According to data available with the stock exchanges, so far this fiscal, 12 firms have raised Rs 27,000 crore from IPOs, and Rs 70,000-crore more issues are in the pipeline. The entire FY21 saw only 30 IPOs raising Rs 31,277 crore. Apart from these pharma firms, Devyani International and and Exxaro Til
Daily cases have grown persistently through July in Kerala and a few smaller north-eastern states
India has so far administered 461,518,479 vaccine doses. That is 1459.85 per cent of its total caseload, and 33.09 per cent of its population
People isolate while desperately trying to identify how the infection is spread
India has so far administered 456,033,754 vaccine doses. That is 1444.4 per cent of its total caseload, and 32.7 per cent of its population
Windlas Biotech, manufacturer of pharmaceutical formulations, on Thursday said it has fixed a price band of Rs 448-460 a share for its initial share-sale. The three-day initial public offer (IPO) will open on August 4 and conclude on August 6, the company announced in a virtual press conference. The IPO comprises fresh issuance of equity shares worth Rs 165 crore and and an offer for sale of up to 5,142,067 equity shares. As a part of the OFS, Vimla Windlass will offload 11.36 lakh equity shares, and investor Tano India Private Equity Fund II will sell 40,06,067 equity shares. At the upper end of the price band, the initial share-sale will fetch Rs 401.53 crore. The proceeds from the IPO will be utilised for purchasing of equipment required for capacity expansion of the facility at Dehradun Plant -IV and addition of injectables dosage capability at the facility at Dehradun Plant-II. It will also be used for funding incremental working capital requirements, repayment/ prepayment o
India averages 109 vaccinations per site and the UK 126. It has fully vaccinated only 6 per cent of its population, as against 53 per cent in the UK
India has so far administered 441,912,395 vaccine doses. That is 1405.53 per cent of its total caseload, and 31.69 per cent of its population
India has so far administered 435,196,001 vaccine doses. That is 1385.47 per cent of its total caseload, and 31.21 per cent of its population
India has so far administered 427,882,261 vaccine doses. That is 1365.63 per cent of its total caseload, and 30.68 per cent of its population